Raid Aljumaily, MD
Dr. Raid Aljumaily is a medical oncologist with a special interest in thoracic oncology. He practices at the Stephenson Cancer Center of Oklahoma University Health in the Department of Hematology/Oncology, treating patients diagnosed with lung cancer, pleural mesothelioma, and other thoracic malignancies. Dr. Aljumaily’s practice is guided by his scientific background, and he works to link his research findings to the treatment of his patients.[1]
Dr. Aljumaily’s clinical interests include thoracic malignancies, lung and esophageal cancers, oligometastatic disease, and non-small cell lung cancer.
Education and Career
Dr. Aljumaily attended medical school at the King Edward Medical College in Baghdad, Iraq, earning bachelor of medicine and bachelor of surgery degrees. Upon his arrival in the United States, he worked for a year as an oncology researcher in the laboratory of Andres Klein-Szanto at Philadelphia’s Fox Chase Cancer Center. He then completed an internship and residency in Internal Medicine at Drexel University College of Medicine and Hahnemann University Hospital in Philadelphia and a fellowship in Hematology/Oncology at Tufts Medical Center in Boston, Massachusetts.
Following completion of his medical education, he joined the Division of Hematology/Oncology at East Carolina University, where he developed a special interest in thoracic oncology after taking care of lung cancer patients. Since arriving at the Stephenson Cancer Center, he has worked to build on his knowledge of the best available treatments for thoracic malignancies, providing compassionate care and working to achieve the best outcomes for his patients. Dr. Aljumaily is also a member of the lung committee of two national cooperative groups, the SWOG and the NRG, and the director of Oklahoma University Health’s fellowship program in the division of Hematology/Oncology.[1]
Research
Dr. Aljumaily is an active researcher, pursuing a phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant chemotherapy, as well as the chair of a national NCI-sponsored clinical trial, S1933, for a novel approach to the treatment of patients with stage 2 and 3 non-small cell lung cancer. He is the primary investigator on most of the thoracic oncology clinical trials being conducted at Stephenson Cancer Center and is also interested in retrospective reviews of past experience in treating patients with non-small cell lung cancer with oligometastatic disease with curative intent.[1]
